Acadian Asset Management
PRLD icon

Acadian Asset Management’s Prelude Therapeutics PRLD Stock Holding History

Acadian Asset Management’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.75M Sell
511,519
-24,184
-5% -$63.4K ﹤0.01% 998
2025
Q4 		$1.55M Sell
535,703
-4,862
-0.9% -$8.21K ﹤0.01% 985
2025
Q3 		$777K Hold
540,565
– – ﹤0.01% 1115
2025
Q2 		$436K Buy
540,565
+11,238
+2% +$9.73K ﹤0.01% 1166
2025
Q1 		$405K Buy
529,327
+43,946
+9% +$41K ﹤0.01% 1117
2024
Q4 		$617K Buy
485,381
+411,238
+555% +$546K ﹤0.01% 1032
2024
Q3 		$152K Buy
74,143
+52,033
+235% +$241K ﹤0.01% 1459
2024
Q2 		$83K Hold
22,110
– – ﹤0.01% 1559
2024
Q1 		$104K Buy
22,110
+6,615
+43% +$25.7K ﹤0.01% 1281
2023
Q4 		$65K Buy
15,495
+8,472
+121% +$25.8K ﹤0.01% 1428
2023
Q3 		$21K Buy
+7,023
New +$26.4K ﹤0.01% 1540

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Acadian Asset Management's PRLD Position: Q1 2026 in Review

Acadian Asset Management reduced its Prelude Therapeutics (PRLD) stake by 4.5% in Q1 2026, selling an estimated $63.4K and leaving 511,519 shares worth $1.75M. The position accounts for ﹤0.01% of the portfolio, ranked #998.

Acadian Asset Management first reported a position in PRLD in Q3 2023 and has held it in 11 quarters since. 55 funds tracked by Wall St. Rank hold PRLD as of Q1 2026.

  • Acadian Asset Management held 511,519 shares of Prelude Therapeutics worth $1.75M as of Q1 2026.
  • Acadian Asset Management sold 24,184 Prelude Therapeutics shares in Q1 2026, an estimated $63.4K.
  • Prelude Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q1 2026, its #998 holding.
  • Acadian Asset Management first reported a position in Prelude Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • 55 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.